Customize
Quick Links

Accreditation/
Credit Designation

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC, designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians’ Education Resource®, LLC is approved by the California Board of Registered Nursing, Provider #16669 for 1.5 Contact Hours.

Acknowledgment of Commercial Support

This activity is supported by an educational grant from Puma Biotechnology.

About
Accreditation
Privacy Policy
Terms & Conditions
Executive Board
Journal
Faculty Portal
Contact
Facebook
Twitter
LinkedIn
Google +
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 800-210-2873

Copyright © 2017
Physicians’ Education Resource ®, LLC.
All rights reserved.

MBCC: Optimizing Outcomes in HER2-Positive Breast Cancer: Emerging Evidence and Practical Strategies in Early-Stage Treatment Settings

MBCC: Optimizing Outcomes in HER2-Positive Breast Cancer: Emerging Evidence and Practical Strategies in Early-Stage Treatment Settings


Date: Saturday, March 10, 2018

Time: 7:00 AM – 8:30 AM
Breakfast and registration: 6:30 AM – 7:00 AM

Location:Fontainebleau Miami Beach
Meeting Room: Fontaine
4441 Collins Avenue
Miami Beach, FL 33140

Program Overview

Although patients with early-stage HER2-positive breast cancer have seen improvement in outcomes with recent advancements in pharmacologic management, there are still significant challenges with the emergence of resistance to HER2-targeted therapies. Recent progression in understanding of the mechanisms of resistance to standard therapies has also helped to direct clinical investigation into pathways and targets to overcome treatment barriers for those with advanced disease. In order to optimize treatment sequencing, clinicians involved in the care of patients with HER2-positive breast cancer must be able to interpret and apply data from recent clinical trials. Even practitioners who have this clinical foundation may require additional assistance with the application of data to real-world clinical scenarios for patients with HER2-positive breast cancer that may not neatly align with clinical trial populations.

In order to help busy clinicians optimize the management of their patients, this activity will feature a series of didactic presentations from prominent experts in the field that will be used as a starting point to discuss the latest data for HER2-positive breast cancer and its implications for clinical practice. Our panel of clinical experts will provide guidance on interpretation of core concepts, address emerging data in HER2-positive breast cancer, and share clinical pearls from their own practices. This program will also include interactive question-and-answer sessions with the faculty.

Acknowledgment of Commercial Support

This activity is supported by an educational grant from Puma Biotechnology.

Target Audience:

This educational activity is directed toward medical oncologists, surgeons, pathologists, and fellows. Nurse practitioners, nurses, physician assistants, pharmacists, researchers, and other healthcare professionals interested in the treatment of breast cancer are invited to participate.

Learning Objectives

After successful completion of this educational activity, participants should be better able to:

  • Relate the rationale underlying the recent development of strategies for the adjuvant treatment of HER2-positive breast cancer
  • Delineate methods to properly characterize HER2-positive breast cancer to inform optimized decision making in patients with early-stage disease
  • Explain outcomes from landmark recent clinical trials conducted in patients with HER2-positive breast cancer that have evaluated adjuvant treatment approaches
  • Apply evidence from key clinical trials to inform decision making concerning the sequencing of adjuvant therapies in the care of patients with early-stage HER2-positive breast cancer


Program Chair

Debu Tripathy, MD
Professor and Chair, Department of Breast Medical Oncology
The University of Texas MD Anderson Cancer Center
Houston, TX







Become a Member

Forgot Password?
Filter By